rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IOVA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Iovance at Jefferies Global Healthcare Conference: sales momentum builds
      Nov 16Investing.comIOVAJEF
      Iovance: The Lung Selloff Went Too Far For A Business Growing 77% (NASDAQ:IOVA)
      Nov 16Seeking AlphaIOVA
      Iovance Biotherapeutics to Present at Upcoming Conference
      Nov 12Yahoo FinanceIOVA
      BrightSpring, Centene stand out as healthcare's most persistent Strong Buys (XLV:NYSEARCA)
      Nov 12Seeking AlphaBTSGBTSGUIOVACNC
      Iovance Earnings Call Signals Strong AMTAGVI Momentum

      Tipranks Press Release.

      Nov 7The Globe and MailIOVA
      Iovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market Reaction (NASDAQ:IOVA)
      Nov 6Seeking AlphaIOVA
      Iovance: Reset Expectations Make The Stock A Buy Again (Rating Upgrade) (NASDAQ:IOVA)
      Nov 6Seeking AlphaIOVA
      IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs
      Nov 6Yahoo FinanceIOVA
      Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ...
      Nov 6Yahoo FinanceIOVA
      Iovance Biotherapeutics (IOVA) Lifileucel Wins Fast Track After Strong Sarcoma Trial Data
      Nov 5Yahoo FinanceIOVA
      Iovance Biotherapeutics Q3 Earnings Call Highlights
      Nov 5Yahoo FinanceIOVA
      Iovance Biotherapeutics Q3 2026 Earnings Call Transcript
      Nov 5BenzingaIOVA
      Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue Estimates
      Nov 5Yahoo FinanceIOVA
      Iovance Biotherapeutics: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceIOVA
      Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
      Nov 5Yahoo FinanceIOVA
      Iovance earnings on deck: Can Amtagvi sustain launch momentum?
      Nov 4Investing.comIOVA
      Iovance Gears Up to Report Q3 Earnings: Here's What to Expect
      Nov 2Yahoo FinanceIOVA
      Iovance Sinks Another 11% as Baird Cuts Target to $9 After Lung Cancer Data
      Oct 30Yahoo FinanceIOVA
      Iovance Biotherapeutics (IOVA) Posts 59.1% Response In Lifileucel Lung Cancer Study
      Oct 30Yahoo FinanceIOVA
      Is 50% Crash Risk For Iovance Stock Real?
      Oct 30Yahoo FinanceIOVA
      Iovance plummets on new phase 2 Amtagvi data for non-small-cell lung cancer

      Iovance stock sank after phase 2 Amtagvi lung cancer data. Read more here.

      Oct 29Seeking AlphaIOVA
      These 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay Away

      Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

      Oct 29The Globe and MailIOVA
      Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer - Slideshow (NASDAQ:IOVA) 2026-10-29

      2026-10-29. The following slide deck was published by Iovance Biotherapeutics, Inc.

      Oct 29Seeking AlphaIOVA
      Iovance Sinks 31% as Lung Cancer TIL Data Comes In “Consistent With Previously Reported Results”
      Oct 29Yahoo FinanceIOVA
      Iovance’s Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filing
      Oct 29Yahoo FinanceIOVA
      Top 1% Biotech Stock Crashes In A Surprise Lung Cancer Twist

      Iovance stock crashed Thursday, undercutting its 50-day line, on new durability questions for its lung cancer treatment.

      Oct 29Investor's Business DailyIOVA
      IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says ‘Selling Is Not Done’ – What’s Driving The Fall?
      Oct 29Yahoo FinanceIOVA
      Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
      Oct 29Yahoo FinanceIOVA
      Iovance reports 24.6% response rate in lung cancer trial
      Oct 29Investing.comIOVA
      Iovance stock falls after lung cancer trial data disappoints
      Oct 29Yahoo FinanceIOVA
      Why is Iovance Biotherapeutics stock sliding today?
      Oct 29Investing.comIOVA
      Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

      24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics License Application (sBLA) for Lifileucel in Non-Squamous mNSCLC in 2027 KRAS Wild-Type Subgroup Achieved 43.3% ORR Versus 11.4% in KRAS-Mutant Disease and Novel Biomarker-Enriched Subgroup Achieved 59.1% ORR POSITILITY, a First-In-Class Biomarker-Enriched Study with Registration

      Oct 29Yahoo FinanceIOVA
      Why Did IOVA Stock Jump Over 10% After-Hours Today?
      Oct 29Yahoo FinanceIOVA
      Melanoma Trial Results Could Be A Game Changer For Iovance Biotherapeutics (IOVA)
      Oct 28Yahoo FinanceIOVA
      Indexes Edge Higher As Fed Stands Pat: Brinker, Medpace, Iovance In Focus - Video - IBD
      Oct 28Investor's Business DailyIOVAMEDPEAT
      Iovance Biotherapeutics (IOVA) Stock Could Look Fully Priced Despite ESMO Data
      Oct 28Yahoo FinanceIOVA
      Iovance Biotherapeutics (IOVA) Could Be 19% Undervalued After Phase 2 Melanoma Data
      Oct 28Yahoo FinanceIOVA
      Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
      Oct 27Yahoo FinanceIOVA
      Iovance reports 50% response rate in sarcoma therapy trial
      Oct 26Investing.comIOVA
      Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
      Oct 26Yahoo FinanceIOVA
      Iovance sees long-term response for Amtagvi in first-line melanoma (IOVA:NASDAQ)

      Phase 2 data show Amtagvi plus Keytruda delivered strong frontline advanced melanoma responses. Read more here.

      Oct 23Seeking AlphaIOVA
      Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
      Oct 23Yahoo FinanceIOVA
      Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End
      Oct 23Yahoo FinanceIOVA
      Iovance Biotherapeutics stock hits 52-week high at 15.32 USD
      Oct 21Investing.comIOVA
      Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026

      Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously Treated Soft Tissue Sarcomas PHILADELPHIA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, wi

      Oct 19Yahoo FinanceIOVA
      Undercovered Dozen: Hess Midstream, Iovance Biotherapeutics, Netlist, And More
      Oct 19Seeking AlphaIOVAHESM
      Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
      Oct 16Yahoo FinanceIOVA
      Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call - Iovance Biotherapeutics (NASDAQ:IO

      Iovance Biotherapeutics (NASDAQ:IOVA) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you

      Oct 6BenzingaIOVA
      Top 3 Health Care Stocks That May Collapse In Q4 - Iovance Biotherapeutics (NASDAQ:IOVA)

      Three healthcare stocks—Quantum-Si, Kodiak Sciences and Iovance—show overbought RSI readings above 80, warning momentum-focused investors.

      Oct 5BenzingaIOVAKODQSI
      Iovance: Buy Now Before Many Growth Catalysts Kick In (NASDAQ:IOVA)

      Iovance raised 2026 revenue guidance as Amtagvi adoption accelerates with broader access, physician awareness, and faster manufacturing. Learn more about IOVA stock here.

      Oct 5Seeking AlphaIOVA

      This is the newest page. Registered accounts read further back.